Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients
To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients. Sixty-four patients were randomly assigned to receive three v...
Uloženo v:
| Vydáno v: | Journal of clinical oncology Ročník 23; číslo 35; s. 8978 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
10.12.2005
|
| Témata: | |
| ISSN: | 0732-183X |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients.
Sixty-four patients were randomly assigned to receive three vaccinations of high-dose or low-dose tumor cells at 3-week intervals. Tumor cell vaccine preparation succeeded for 56 patients (88%), but because of progressive disease, the well-tolerated vaccination was completed in only 28 patients. We analyzed the priming of T cells against melanoma antigens, MART-1, tyrosinase, gp100, MAGE-A1, and MAGE-A3 using human leukocyte antigen/peptide tetramers and functional assays.
The high-dose vaccination induced the infiltration of T cells into the tumor tissue. Three of 14 patients receiving the high-dose vaccine showed an increase in MART-1- or gp100-specific T cells in the peripheral blood during vaccination. Six patients experienced disease-free survival for more than 5 years, and two of these patients developed vitiligo at multiple sites after vaccination. MART-1- and gp100-specific T cells were found infiltrating in vitiligo skin. Upon vaccination, the T cells acquired an effector phenotype and produced interferon-gamma on specific antigenic stimulation.
We conclude that vaccination with GM-CSF-transduced autologous tumor cells has limited toxicity and can enhance T-cell activation against melanocyte differentiation antigens, which can lead to vitiligo. Whether the induction of autoimmune vitiligo may prolong disease-free survival of metastatic melanoma patients who are surgically rendered as having no evidence of disease before vaccination is worthy of further investigation. |
|---|---|
| AbstractList | To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients.PURPOSETo determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients.Sixty-four patients were randomly assigned to receive three vaccinations of high-dose or low-dose tumor cells at 3-week intervals. Tumor cell vaccine preparation succeeded for 56 patients (88%), but because of progressive disease, the well-tolerated vaccination was completed in only 28 patients. We analyzed the priming of T cells against melanoma antigens, MART-1, tyrosinase, gp100, MAGE-A1, and MAGE-A3 using human leukocyte antigen/peptide tetramers and functional assays.PATIENTS AND METHODSSixty-four patients were randomly assigned to receive three vaccinations of high-dose or low-dose tumor cells at 3-week intervals. Tumor cell vaccine preparation succeeded for 56 patients (88%), but because of progressive disease, the well-tolerated vaccination was completed in only 28 patients. We analyzed the priming of T cells against melanoma antigens, MART-1, tyrosinase, gp100, MAGE-A1, and MAGE-A3 using human leukocyte antigen/peptide tetramers and functional assays.The high-dose vaccination induced the infiltration of T cells into the tumor tissue. Three of 14 patients receiving the high-dose vaccine showed an increase in MART-1- or gp100-specific T cells in the peripheral blood during vaccination. Six patients experienced disease-free survival for more than 5 years, and two of these patients developed vitiligo at multiple sites after vaccination. MART-1- and gp100-specific T cells were found infiltrating in vitiligo skin. Upon vaccination, the T cells acquired an effector phenotype and produced interferon-gamma on specific antigenic stimulation.RESULTSThe high-dose vaccination induced the infiltration of T cells into the tumor tissue. Three of 14 patients receiving the high-dose vaccine showed an increase in MART-1- or gp100-specific T cells in the peripheral blood during vaccination. Six patients experienced disease-free survival for more than 5 years, and two of these patients developed vitiligo at multiple sites after vaccination. MART-1- and gp100-specific T cells were found infiltrating in vitiligo skin. Upon vaccination, the T cells acquired an effector phenotype and produced interferon-gamma on specific antigenic stimulation.We conclude that vaccination with GM-CSF-transduced autologous tumor cells has limited toxicity and can enhance T-cell activation against melanocyte differentiation antigens, which can lead to vitiligo. Whether the induction of autoimmune vitiligo may prolong disease-free survival of metastatic melanoma patients who are surgically rendered as having no evidence of disease before vaccination is worthy of further investigation.CONCLUSIONWe conclude that vaccination with GM-CSF-transduced autologous tumor cells has limited toxicity and can enhance T-cell activation against melanocyte differentiation antigens, which can lead to vitiligo. Whether the induction of autoimmune vitiligo may prolong disease-free survival of metastatic melanoma patients who are surgically rendered as having no evidence of disease before vaccination is worthy of further investigation. To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients. Sixty-four patients were randomly assigned to receive three vaccinations of high-dose or low-dose tumor cells at 3-week intervals. Tumor cell vaccine preparation succeeded for 56 patients (88%), but because of progressive disease, the well-tolerated vaccination was completed in only 28 patients. We analyzed the priming of T cells against melanoma antigens, MART-1, tyrosinase, gp100, MAGE-A1, and MAGE-A3 using human leukocyte antigen/peptide tetramers and functional assays. The high-dose vaccination induced the infiltration of T cells into the tumor tissue. Three of 14 patients receiving the high-dose vaccine showed an increase in MART-1- or gp100-specific T cells in the peripheral blood during vaccination. Six patients experienced disease-free survival for more than 5 years, and two of these patients developed vitiligo at multiple sites after vaccination. MART-1- and gp100-specific T cells were found infiltrating in vitiligo skin. Upon vaccination, the T cells acquired an effector phenotype and produced interferon-gamma on specific antigenic stimulation. We conclude that vaccination with GM-CSF-transduced autologous tumor cells has limited toxicity and can enhance T-cell activation against melanocyte differentiation antigens, which can lead to vitiligo. Whether the induction of autoimmune vitiligo may prolong disease-free survival of metastatic melanoma patients who are surgically rendered as having no evidence of disease before vaccination is worthy of further investigation. |
| Author | Sein, Johan Luiten, Rosalie M Clift, Shirley M Gerritsen, Winald R Weder, Pauline de Gast, Gijsbert C Berns, Anton M Gallee, Maarten P W van den Berk, Paul C M Rankin, Elaine M Nooijen, Willem J Kueter, Esther W M Spits, Hergen van de Kasteele, Willeke F Mooi, Wolter Nieweg, Omgo E |
| Author_xml | – sequence: 1 givenname: Rosalie M surname: Luiten fullname: Luiten, Rosalie M organization: Clinical Immunotherapy, Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands – sequence: 2 givenname: Esther W M surname: Kueter fullname: Kueter, Esther W M – sequence: 3 givenname: Wolter surname: Mooi fullname: Mooi, Wolter – sequence: 4 givenname: Maarten P W surname: Gallee fullname: Gallee, Maarten P W – sequence: 5 givenname: Elaine M surname: Rankin fullname: Rankin, Elaine M – sequence: 6 givenname: Winald R surname: Gerritsen fullname: Gerritsen, Winald R – sequence: 7 givenname: Shirley M surname: Clift fullname: Clift, Shirley M – sequence: 8 givenname: Willem J surname: Nooijen fullname: Nooijen, Willem J – sequence: 9 givenname: Pauline surname: Weder fullname: Weder, Pauline – sequence: 10 givenname: Willeke F surname: van de Kasteele fullname: van de Kasteele, Willeke F – sequence: 11 givenname: Johan surname: Sein fullname: Sein, Johan – sequence: 12 givenname: Paul C M surname: van den Berk fullname: van den Berk, Paul C M – sequence: 13 givenname: Omgo E surname: Nieweg fullname: Nieweg, Omgo E – sequence: 14 givenname: Anton M surname: Berns fullname: Berns, Anton M – sequence: 15 givenname: Hergen surname: Spits fullname: Spits, Hergen – sequence: 16 givenname: Gijsbert C surname: de Gast fullname: de Gast, Gijsbert C |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16260696$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1UD1PwzAQ9VBEP2BnQp6YmmDHiZOMKKKlqKgDILFFjnMORoldYqeo_4KfTBBleu9O7-69uzmaGGsAoStKQhoRcvtY7MIRk5DQkGeUT9CMpCwKaMbepmju3AchNM5Yco6mlEec8JzP0Pem6wZjGzBaan9cYm1kO9TaNPigvW51Y5dYmBorEE5XY8MfsVX4IKTURnhtDf7S_h2LwdvWNnZweP0UFM-rwPfCuHqQUGM_dLbHEtrWjQa4Ay-cH4flSFthbCfwfizBeHeBzpRoHVyecIFeV_cvxUOw3a03xd02kCzJfcBIKqpagUqiihLJeKxICjxPIaYxEbyiEc8UTSIBOa0gSbKcKsoVY6mK8wSiBbr527vv7ecAzpeddr8JhYHxiJJnWZZSwkbh9Uk4VB3U5b7XneiP5f8Pox99U3au |
| CitedBy_id | crossref_primary_10_1016_j_cyto_2023_156268 crossref_primary_10_3322_caac_20132 crossref_primary_10_1586_14760584_7_7_937 crossref_primary_10_1586_14760584_2014_953063 crossref_primary_10_1080_08830185_2020_1775827 crossref_primary_10_1002_ijc_28973 crossref_primary_10_1111_j_1365_4632_2009_03987_x crossref_primary_10_1038_nrclinonc_2013_208 crossref_primary_10_1158_1078_0432_CCR_08_1231 crossref_primary_10_1016_j_jocn_2009_11_017 crossref_primary_10_2217_imt_09_43 crossref_primary_10_3390_ijms160510578 crossref_primary_10_1016_j_humimm_2009_01_017 crossref_primary_10_1097_01_cmr_0000222590_68234_1d crossref_primary_10_1080_08830180600743081 crossref_primary_10_1080_08830180600992498 crossref_primary_10_1016_j_jaad_2016_08_064 crossref_primary_10_1016_j_vaccine_2007_06_041 crossref_primary_10_1186_s12967_015_0572_3 crossref_primary_10_1200_JCO_2005_03_8307 crossref_primary_10_1186_s12985_014_0201_4 crossref_primary_10_3109_08830185_2014_952413 crossref_primary_10_3390_biom12070952 crossref_primary_10_1186_s40164_025_00662_3 crossref_primary_10_1093_jnci_djs033 crossref_primary_10_1158_2326_6066_CIR_13_0097 crossref_primary_10_1007_s00262_007_0407_z crossref_primary_10_1111_1346_8138_15345 crossref_primary_10_1111_1346_8138_13520 crossref_primary_10_1007_s00262_020_02780_9 crossref_primary_10_1016_j_arr_2019_100981 crossref_primary_10_4049_jimmunol_0901447 crossref_primary_10_1186_1471_2288_11_117 crossref_primary_10_4049_jimmunol_0902778 crossref_primary_10_1016_j_jid_2020_01_033 crossref_primary_10_5301_tj_5000253 crossref_primary_10_1016_j_vaccine_2007_06_033 crossref_primary_10_1093_annonc_mdp325 crossref_primary_10_1016_j_virol_2012_01_025 crossref_primary_10_1038_sj_gt_3303026 crossref_primary_10_1002_jgm_1094 crossref_primary_10_1517_14712598_2010_495383 crossref_primary_10_2217_imt_14_95 crossref_primary_10_1016_j_cytogfr_2007_01_016 crossref_primary_10_3390_ijms24065208 crossref_primary_10_1007_s11748_008_0433_6 crossref_primary_10_1200_JCO_2014_57_4756 crossref_primary_10_1586_erv_11_74 crossref_primary_10_1158_1078_0432_CCR_05_2682 crossref_primary_10_1016_j_immuni_2016_10_026 crossref_primary_10_1586_era_10_66 crossref_primary_10_1111_j_1600_0749_2006_00334_x crossref_primary_10_1586_14760584_2014_911093 crossref_primary_10_1111_j_1600_065X_2008_00618_x crossref_primary_10_1002_adhm_201701148 crossref_primary_10_1097_CMR_0000000000000535 crossref_primary_10_1038_jid_2009_32 crossref_primary_10_1634_theoncologist_12_S2_22 crossref_primary_10_1084_jem_20231717 crossref_primary_10_1158_1078_0432_CCR_08_3320 crossref_primary_10_1186_s13058_018_1054_3 crossref_primary_10_1080_2162402X_2021_1920739 crossref_primary_10_3390_vaccines9060668 crossref_primary_10_1093_annonc_mdl158 crossref_primary_10_1517_14712598_7_3_345 crossref_primary_10_1245_s10434_006_9196_4 crossref_primary_10_1371_journal_pone_0010626 crossref_primary_10_1016_j_autrev_2006_03_012 crossref_primary_10_2217_mmt_2020_0011 crossref_primary_10_1038_cgt_2011_22 crossref_primary_10_1016_j_biomaterials_2019_119417 crossref_primary_10_1111_j_1349_7006_2009_01202_x crossref_primary_10_1182_blood_2006_12_061309 crossref_primary_10_1016_j_smim_2010_03_003 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2005.01.6816 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| ExternalDocumentID | 16260696 |
| Genre | Clinical Trial, Phase II Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 08P 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 8WZ A6W AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AWKKM AZFZN BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N4W N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VH1 VVN WH7 X7M YCJ YFH YQY ZGI 7X8 ABBLC |
| ID | FETCH-LOGICAL-c359t-307abdfef52b10c364f07e697e4140a6b1268f152ae91be55891f16f337f495e2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 98 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000234026500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0732-183X |
| IngestDate | Thu Sep 04 17:15:19 EDT 2025 Sat Sep 28 07:57:59 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 35 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c359t-307abdfef52b10c364f07e697e4140a6b1268f152ae91be55891f16f337f495e2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 16260696 |
| PQID | 68887103 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_68887103 pubmed_primary_16260696 |
| PublicationCentury | 2000 |
| PublicationDate | 2005-12-10 |
| PublicationDateYYYYMMDD | 2005-12-10 |
| PublicationDate_xml | – month: 12 year: 2005 text: 2005-12-10 day: 10 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2005 |
| References | 16260688 - J Clin Oncol. 2005 Dec 10;23(35):8929-31 |
| References_xml | – reference: 16260688 - J Clin Oncol. 2005 Dec 10;23(35):8929-31 |
| SSID | ssj0014835 |
| Score | 2.1788757 |
| Snippet | To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 8978 |
| SubjectTerms | Adjuvants, Immunologic Adult Aged Antigens, Neoplasm - immunology Autoimmune Diseases - etiology Cancer Vaccines - adverse effects Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Cytotoxicity, Immunologic Drug Administration Schedule Feasibility Studies Female Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects Granulocyte-Macrophage Colony-Stimulating Factor - immunology Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use Humans Male Melanoma - drug therapy Melanoma - immunology Middle Aged Neoplasm Proteins - immunology Peptide Fragments - immunology T-Lymphocytes - immunology Vitiligo - etiology |
| Title | Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/16260696 https://www.proquest.com/docview/68887103 |
| Volume | 23 |
| WOSCitedRecordID | wos000234026500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Ja9tAFH5kKSGXJE2zNknfoeRkxR7JGo2gEIKJ0xbsGpqCb2Y0SxDYUhLJBv-L_uS8kWR8Kj3kIiTQMCPep7cvAF-FCTWLY03crxs6b5XwhFYdL9JSCFLPScjUwyai4VCMx_FoA76tamFcWuWKJ1aMWufK-cjbnEw1kobB7fOL52ZGudhqM0BjE7YDUmQcpqPxOoZAG1cJjFHgewTccROkJFi0f_Z-Ne4UdsMF4_9WLysx099_3wEPYK9RL_GuxsNH2DDZIewMmgD6IVyP6lbVyxY-riuvihZe42jdxHr5Cf7-cIUjOcGLVpb0epqp6dwJOlykZTpNn_IWykyjNbLJsF1ibnEhFe1UkRudjxflvJqQm88LfBh4vd99r3TiUROkNJbzWf6KLnhQ0AY4M6V0FU6potupzPKZxKbxa3EEf_r3j73vXjO9wVNBGJfOqSUTbY0N_YR1VMC7thMZHkemS0ad5AnzubCkPkgTs8SEbryhZdwGQWTJajP-MWxleWZOAaUlLUQwZUn96hqZxFzRYnqKNOO-5GfwZUWSCf0d7tQyM_RhkxVRzuCkpurkuW7iMWHOkuMxP__v2s-wW_drJRh1LmDbEl8wl_BBLcq0eL2qQEfX4WjwBh9T44A |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunogenicity%2C+including+vitiligo%2C+and+feasibility+of+vaccination+with+autologous+GM-CSF-transduced+tumor+cells+in+metastatic+melanoma+patients&rft.jtitle=Journal+of+clinical+oncology&rft.au=Luiten%2C+Rosalie+M&rft.au=Kueter%2C+Esther+W+M&rft.au=Mooi%2C+Wolter&rft.au=Gallee%2C+Maarten+P+W&rft.date=2005-12-10&rft.issn=0732-183X&rft.volume=23&rft.issue=35&rft.spage=8978&rft_id=info:doi/10.1200%2FJCO.2005.01.6816&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |